Predictive Oncology (NASDAQ:POAI) Shares Pass Below 200 Day Moving Average – What’s Next?

Predictive Oncology Inc. (NASDAQ:POAI) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $7.86 and traded as low as $1.69. Predictive Oncology shares last traded at $1.83, with a volume of 41,146 shares.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered Predictive Oncology to a “strong sell” rating in a research report on Saturday, December 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Predictive Oncology has an average rating of “Sell”.

Predictive Oncology Stock Performance

The company has a market cap of $6.21 million, a PE ratio of -0.14 and a beta of 1.35. The stock’s 50 day moving average price is $4.07 and its 200-day moving average price is $7.86.

Predictive Oncology Company Profile

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.